89Bio, Inc. Stock Price, News & Analysis

89bio to Host KOL Webinar on Severe Hypertriglyceridemia

SAN FRANCISCO, April 26, 2022 – 89bio, a clinical-stage biopharmaceutical company (Nasdaq: ETNB), has announced a webinar scheduled for May 4, 2022, at 11:00 a.m. PT/2:00 p.m. ET. The event will feature presentations from renowned experts Harold Bays, MD, and Deepak L. Bhatt, MD, covering the treatment landscape for severe hypertriglyceridemia (SHTG) and the ENTRIGUE Phase 2 clinical trial of 89bio’s candidate pegozafermin. A Q&A session will also be included, emphasizing the clinical and regulatory development pathway for this innovative therapy.

89bio reported significant advancements in its clinical programs, revealing positive topline results from cohort 7 in the Phase 1b/2a NASH trial for pegozafermin. The data showed that 74% of patients achieved a 2-point or greater improvement in NAFLD Activity Score. The company anticipates topline data from the ENLIVEN Phase 2b NASH trial in the first half of 2023 and has closed enrollment in the ENTRIGUE trial, with results expected in Q2 2022. Financially, the company reported a net loss of $90.1 million for 2021, an increase attributed to higher R&D and G&A expenses.

89bio, Inc. (Nasdaq: ETNB) announced the appointment of E. Morrey Atkinson, Ph.D., to its Board of Directors. Dr. Atkinson, with over 20 years of expertise in biopharmaceutical development and manufacturing, previously held senior roles at Vertex and Bristol Myers Squibb. CEO Rohan Palekar emphasized Atkinson’s valuable experience in optimizing manufacturing and commercializing therapies. This comes after promising data from the Phase 1b/2a study of 89bio's lead candidate, pegozafermin, targeting liver diseases like NASH and SHTG.

89bio, a clinical-stage biopharmaceutical company (Nasdaq: ETNB), announced its participation in the SVB Leerink 11th Annual Global Healthcare Conference on February 16, 2022, at 12:00 PM ET. The management team will engage in a fireside chat and one-on-one investor meetings. A presentation will be available via the conference portal and archived on its website.

89bio, focused on therapies for liver and cardio-metabolic diseases, announced positive results from a Phase 1b/2a study of pegozafermin for treating NASH. In an expansion cohort of 20 patients, 63% achieved a 2-point improvement in NAS without worsening fibrosis, with 32% showing NASH resolution. The treatment also showed significant changes in liver health and cardio-metabolic markers, with pegozafermin being generally well tolerated. The ongoing Phase 2b ENLIVEN trial is expected to provide further insights, with results anticipated in the first half of 2023.

89bio, Inc. (Nasdaq: ETNB) recently presented findings from the Phase 1b/2a study of BIO89-100 at The Liver Meeting 2021, revealing a significant average reduction of 11.8% in spleen volume among NASH patients. This post-hoc analysis establishes a correlation between liver fat reduction and decreased spleen volume, suggesting improved portal blood flow as a mechanism. The oral presentation was recognized by the AASLD as a key presentation at the event. With promising preliminary data, 89bio aims to further explore BIO89-100's therapeutic potential for NASH.

89bio, Inc. (Nasdaq: ETNB) reported its Q3 2021 financial results, highlighting significant advancements in its clinical program for BIO89-100, targeted at liver and cardio-metabolic diseases. The company plans to release data from its NASH study in January 2022 and from its SHTG study in the first half of 2022. As of September 30, 2021, 89bio had $157.4 million in cash but reported a net loss of $28.3 million for Q3 2021, an increase from the previous year, mainly due to rising R&D and G&A expenses.

89bio, Inc. (Nasdaq: ETNB) has appointed Kathy LaPorte to its Board of Directors, effective immediately. LaPorte brings over 30 years of biotech industry experience, enhancing operational capabilities and driving growth. CEO Rohan Palekar praised her expertise as invaluable for advancing the ongoing clinical development of BIO89-100, a potential treatment for NASH. LaPorte's background includes leadership roles in various biotech boards and a strong record in venture investing.

This strategic appointment aims to bolster 89bio's efforts in developing innovative therapies for liver and cardio-metabolic diseases.

89bio, Inc. (ETNB) announced new findings from a sub-analysis of its Phase 1b/2a study on BIO89-100 for non-alcoholic steatohepatitis (NASH), revealing a correlation between increased liver fat and spleen volume. The results will be presented at the AASLD The Liver Meeting 2021, taking place virtually from November 12-15, 2021. Additionally, the population pharmacokinetics and pharmacodynamics of BIO89-100 will be showcased. This treatment is engineered to enhance the biological activity of FGF21, aimed at addressing the root causes of NASH and severe hypertriglyceridemia.